These findings suggest that CRC cancers with co-occurring KRAS and PIK3CA mutations, which is not a frequent entity [5], may be particularly susceptible to parallel apoptotic and pro-survival effects with this combination treatment. Here, KRAS is linked to colorectal carcinoma.